Therapeutic area data reported by biopharma companies on phase III trials in January 2020, including: Abbvie, Astrazeneca, Beigene, Biofrontera, Eli Lilly, EMD Serono, Erytech, Evolus, Incyte, Innovent, Isofol Medical, Kala, Kyowa Kirin, Lipidor, Merck, Nucana, Orion, Rafael, Roche, Sellas Life Sciences, VBL, Verastem.